Key result
Empagliflozin improves diastolic relaxation by ~11% and reduces LV mass in nondiabetic HFpEF rodents.
Why the study?
SGLT2 inhibitors prevent heart failure hospitalization in patients with type 2 diabetes, but the underlying mechanisms remain unclear.
Does empagliflozin improve diastolic function and reduce left ventricular mass in a nondiabetic rodent model of HFpEF?
Does empagliflozin improve diastolic function and reduce left ventricular mass in a nondiabetic rodent model of HFpEF?
Empagliflozin improves hemodynamics and diastolic function in a nondiabetic HFpEF rodent model, providing a mechanistic rationale for its use in HFpEF regardless of diabetes status.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for empagliflozin in nondiabetic HFpEF; prospective human trials needed before clinical adoption.
Recent studies send an unambiguous signal that the class of agents known as sodium-glucose-linked co-transporter-2 inhibitors (SGLT2i) prevent heart failure hospitalization in patients with type 2 diabetes. However, the mechanisms remain unclear. Herein the authors utilize a rodent model of heart failure with preserved ejection fraction (HFpEF), and demonstrate that treatment with the SGLT2i empagliflozin, reduces left ventricular mass, improving both wall stress and diastolic function. These findings extend the observation that the main mechanism of action of empagliflozin involves improved hemodynamics (i.e., reduction in preload and afterload) and provide a rationale for upcoming trials in patients with HFpEF irrespective of glycemic status.
No takes yet. Share an insight, caveat, or question.
Connelly et al. (2019) studied Heart failure with preserved ejection fraction (HFpEF) (n=46). Empagliflozin vs. Control diet (vehicle) was evaluated on Diastolic function (time constant of relaxation, Tau) in ms (p=<0.05). Empagliflozin improved cardiac diastolic function, reducing the time constant of relaxation (Tau) from 15.1 ms to 13.5 ms, and reduced left ventricular mass in a nondiabetic rodent model of HFpEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: